Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 96

1.

Immunotherapeutic strategies to target prognostic and predictive markers of cancer.

Magee MS, Snook AE, Marszalowicz GP, Waldman SA.

Biomark Med. 2013 Feb;7(1):23-35. doi: 10.2217/bmm.12.110. Review.

2.

[Immunological tumor therapy].

Dietrich K, Theobald M.

Internist (Berl). 2015 Aug;56(8):907-16; quiz 917. doi: 10.1007/s00108-015-3744-6. Review. German.

PMID:
26187335
3.

New approaches for cancer immunotherapy.

Karlitepe A, Ozalp O, Avci CB.

Tumour Biol. 2015 Jun;36(6):4075-8. doi: 10.1007/s13277-015-3491-2. Epub 2015 May 2. Review.

PMID:
25934338
4.

MUC1 immunotherapy.

Beatson RE, Taylor-Papadimitriou J, Burchell JM.

Immunotherapy. 2010 May;2(3):305-27. doi: 10.2217/imt.10.17. Review.

PMID:
20635898
5.

Vaccines and immunotherapeutics for the treatment of malignant disease.

Aldrich JF, Lowe DB, Shearer MH, Winn RE, Jumper CA, Kennedy RC.

Clin Dev Immunol. 2010;2010:697158. doi: 10.1155/2010/697158. Epub 2010 Sep 26. Review.

6.

Human cancer detection and immunotherapy with conjugated and non-conjugated monoclonal antibodies.

Bodey B, Siegel SE, Kaiser HE.

Anticancer Res. 1996 Mar-Apr;16(2):661-74. Review.

PMID:
8687112
7.

[Immunotherapy for cancer--modern immunologic strategies in oncology].

Halama N, Zoernig I, J├Ąger D.

Dtsch Med Wochenschr. 2008 Oct;133(41):2105-8. doi: 10.1055/s-0028-1091251. Epub 2008 Oct 1. Review. German.

PMID:
18985564
8.

Cancer immunotherapy: a treatment for the masses.

Blattman JN, Greenberg PD.

Science. 2004 Jul 9;305(5681):200-5. Review.

PMID:
15247469
9.

Cancer immunotherapy.

Schuster M, Nechansky A, Kircheis R.

Biotechnol J. 2006 Feb;1(2):138-47. Review.

PMID:
16892244
10.

Cancer immunotherapy comes of age.

Mellman I, Coukos G, Dranoff G.

Nature. 2011 Dec 21;480(7378):480-9. doi: 10.1038/nature10673. Review.

11.

Immunotherapy in nonmelanoma skin cancer.

Ghafouri-Fard S, Ghafouri-Fard S.

Immunotherapy. 2012 May;4(5):499-510. doi: 10.2217/imt.12.29. Review.

PMID:
22642333
12.

Melanoma immunotherapy: historical precedents, recent successes and future prospects.

Raaijmakers MI, Rozati S, Goldinger SM, Widmer DS, Dummer R, Levesque MP.

Immunotherapy. 2013 Feb;5(2):169-82. doi: 10.2217/imt.12.162. Review.

PMID:
23413908
13.

Production of recombinant immunotherapeutics for anticancer treatment: the role of bioengineering.

Pranchevicius MC, Vieira TR.

Bioengineered. 2013 Sep-Oct;4(5):305-12. doi: 10.4161/bioe.24666. Epub 2013 Apr 22. Review.

14.

The need for improvement of the treatment of advanced and metastatic cervical cancer, the rationale for combined chemo-immunotherapy.

van Meir H, Kenter GG, Burggraaf J, Kroep JR, Welters MJ, Melief CJ, van der Burg SH, van Poelgeest MI.

Anticancer Agents Med Chem. 2014 Feb;14(2):190-203. Review.

PMID:
24237223
15.

Monoclonal antibodies: versatile platforms for cancer immunotherapy.

Weiner LM, Surana R, Wang S.

Nat Rev Immunol. 2010 May;10(5):317-27. doi: 10.1038/nri2744. Review.

16.

Molecular imaging biomarkers for cell-based immunotherapies.

Haris M, Bagga P, Hariharan H, McGettigan-Croce B, Johnson LA, Reddy R.

J Transl Med. 2017 Jun 19;15(1):140. doi: 10.1186/s12967-017-1240-6. Review.

17.

Combinatorial treatments including vaccines, chemotherapy and monoclonal antibodies for cancer therapy.

Baxevanis CN, Perez SA, Papamichail M.

Cancer Immunol Immunother. 2009 Mar;58(3):317-24. doi: 10.1007/s00262-008-0576-4. Epub 2008 Aug 15. Review.

PMID:
18704409
18.

Antibody-based immunotherapy of cancer.

Weiner LM, Murray JC, Shuptrine CW.

Cell. 2012 Mar 16;148(6):1081-4. doi: 10.1016/j.cell.2012.02.034. Review.

19.
20.

Tumor-specific antigens and immunologic adjuvants in cancer immunotherapy.

Seremet T, Brasseur F, Coulie PG.

Cancer J. 2011 Sep-Oct;17(5):325-30. doi: 10.1097/PPO.0b013e3182326004. Review.

PMID:
21952282

Supplemental Content

Support Center